Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)
January 23, 2023 03:21 PM EST
Deals

How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

Nicole DeFeudis

Editor

Cin­Cor scored a $1.8 bil­lion buy­out deal with As­traZeneca ear­li­er this month, but ac­cord­ing to re­cent­ly re­leased doc­u­ments, it al­most walked away from the deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times